Latest Insider Transactions at Catalent, Inc. (CTLT)
This section provides a real-time view of insider transactions for Catalent, Inc. (CTLT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Catalent, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Catalent, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 26
2022
|
John R Chiminski Executive Chair |
SELL
Open market or private sale
|
Direct |
9,691
-6.82%
|
$1,027,246
$106.9 P/Share
|
|
Jul 26
2022
|
Thomas P Castellano SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,323
+11.79%
|
-
|
|
Jul 26
2022
|
Thomas P Castellano SVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
347
-2.25%
|
$36,782
$106.9 P/Share
|
|
Jul 26
2022
|
Lorenzo Carletti SVP Global Ops Ph & Cons Hlth |
BUY
Grant, award, or other acquisition
|
Direct |
837
+18.11%
|
-
|
|
Jul 26
2022
|
Lorenzo Carletti SVP Global Ops Ph & Cons Hlth |
SELL
Open market or private sale
|
Direct |
631
-17.63%
|
$66,886
$106.9 P/Share
|
|
Jul 26
2022
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
BUY
Grant, award, or other acquisition
|
Direct |
1,023
+2.02%
|
-
|
|
Jul 26
2022
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Open market or private sale
|
Direct |
94
-0.19%
|
$9,964
$106.9 P/Share
|
|
Jul 01
2022
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
18,689
+18.9%
|
$1,999,723
$107.02 P/Share
|
|
Jul 01
2022
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
BUY
Grant, award, or other acquisition
|
Direct |
2,804
+5.43%
|
$300,028
$107.02 P/Share
|
|
Jun 10
2022
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.17%
|
$535,000
$107.15 P/Share
|
|
Jun 10
2022
|
Mario Gargiulo SVP, Ops, Biologics Europe |
SELL
Open market or private sale
|
Direct |
118
-2.48%
|
$12,508
$106.59 P/Share
|
|
Feb 06
2022
|
Peter Zippelius Director |
SELL
Open market or private sale
|
Indirect |
487,092
-10.11%
|
$49,683,384
$102.65 P/Share
|
|
Jan 31
2022
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
2,325
-11.99%
|
$239,475
$103.39 P/Share
|
|
Jan 21
2022
|
Ricci S Whitlow President, CSS |
SELL
Open market or private sale
|
Direct |
184
-5.92%
|
$18,768
$102.37 P/Share
|
|
Jan 10
2022
|
Karen Flynn Director |
SELL
Open market or private sale
|
Direct |
2,472
-6.93%
|
$286,752
$116.64 P/Share
|
|
Jan 03
2022
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
BUY
Grant, award, or other acquisition
|
Direct |
4,017
+8.03%
|
-
|
|
Jan 03
2022
|
Steven L Fasman EVP & Chief Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,017
+6.16%
|
-
|
|
Jan 03
2022
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
4,017
+6.13%
|
-
|
|
Jan 03
2022
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
4,017
+19.56%
|
-
|
|
Jan 03
2022
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
4,017
+15.39%
|
-
|
|
Jan 03
2022
|
Ricardo Pravda Chief Transformation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,017
+20.31%
|
-
|
|
Nov 30
2021
|
Peter Zippelius Director |
SELL
Open market or private sale
|
Indirect |
3,000,000
-38.35%
|
$387,000,000
$129.3 P/Share
|
|
Nov 29
2021
|
J Martin Carroll Director |
BUY
Other acquisition or disposition
|
Indirect |
3,136
+21.19%
|
$420,224
$134.12 P/Share
|
|
Nov 29
2021
|
J Martin Carroll Director |
SELL
Other acquisition or disposition
|
Indirect |
3,136
-100.0%
|
$420,224
$134.12 P/Share
|
|
Nov 29
2021
|
J Martin Carroll Director |
BUY
Bona fide gift
|
Indirect |
3,136
+50.0%
|
-
|
|
Nov 29
2021
|
J Martin Carroll Director |
SELL
Bona fide gift
|
Direct |
3,136
-16.07%
|
-
|
|
Nov 23
2021
|
Gregory T Lucier Director |
SELL
Open market or private sale
|
Indirect |
5,068
-76.32%
|
$643,636
$127.37 P/Share
|
|
Nov 18
2021
|
Peter Zippelius Director |
BUY
Conversion of derivative security
|
Indirect |
7,822,946
+50.0%
|
$383,324,354
$49.54 P/Share
|
|
Nov 01
2021
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Open market or private sale
|
Direct |
10,672
-20.27%
|
$1,494,080
$140.02 P/Share
|
|
Nov 01
2021
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
BUY
Exercise of conversion of derivative security
|
Direct |
7,559
+3.65%
|
$332,596
$44.27 P/Share
|
|
Oct 28
2021
|
Madhavan Balachandran Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+7.92%
|
-
|
|
Oct 28
2021
|
Michael J Barber Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+38.42%
|
-
|
|
Oct 28
2021
|
J Martin Carroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+6.7%
|
-
|
|
Oct 28
2021
|
Rolf A Classon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+4.18%
|
-
|
|
Oct 28
2021
|
Rosemary A Crane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+9.92%
|
-
|
|
Oct 28
2021
|
John J Greisch Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+9.92%
|
-
|
|
Oct 28
2021
|
Christa Kreuzburg Director |
SELL
Payment of exercise price or tax liability
|
Direct |
638
-6.4%
|
$86,130
$135.5 P/Share
|
|
Oct 28
2021
|
Christa Kreuzburg Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+12.33%
|
-
|
|
Oct 28
2021
|
Gregory T Lucier Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+6.23%
|
-
|
|
Oct 28
2021
|
Donald E Morel Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+2.52%
|
-
|
|
Oct 28
2021
|
Jack L Stahl Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+4.18%
|
-
|
|
Oct 28
2021
|
Peter Zippelius Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+15.19%
|
-
|
|
Oct 20
2021
|
Thomas P Castellano SVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,307
-13.03%
|
$309,138
$134.0 P/Share
|
|
Oct 14
2021
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Open market or private sale
|
Direct |
1,661
-3.55%
|
$214,269
$129.41 P/Share
|
|
Oct 04
2021
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
34,714
-10.88%
|
$4,478,106
$129.79 P/Share
|
|
Oct 04
2021
|
Steven L Fasman EVP & Chief Admin Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,259
+4.78%
|
$949,245
$55.74 P/Share
|
|
Oct 04
2021
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Open market or private sale
|
Direct |
2,191
-13.72%
|
$287,021
$131.25 P/Share
|
|
Oct 01
2021
|
John R Chiminski Executive Chair |
SELL
Open market or private sale
|
Direct |
152,637
-9.39%
|
$19,842,810
$130.19 P/Share
|
|
Oct 01
2021
|
John R Chiminski Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
75,838
+8.55%
|
$2,881,844
$38.27 P/Share
|
|
Oct 01
2021
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
2,055
-3.67%
|
$267,150
$130.19 P/Share
|